Rutgers logo
Rutgers logo
Rutgers logo
Rutgers logo

About Vivien M. Hsu, MD

Affiliations & Leadership:

  • Acting Division Chief, RWJMS Rheumatology, October 2022-present

 

Education and Training:

  • Undergraduate: Rutgers University, 1978
  • Medical School: New Jersey Medical School, 1983
  • Internal Medicine Residency:  University of California- Irvine, University Hospital, Newark, NJ 1986
  • Rheumatology Fellowship, Rutgers-Robert Wood Johnson Medical School, 1992

 

Honors and Awards:

  • Educator of the Year Award, Rheumatology, 2023
  • Research Mentor of the Year Award, 2022-2023
  • NJ Top Doctor 2024, 2023, 2022, 2018, 2017, 2012, 2011, 2010
  • Best Doctors in America, 2020, 2019, 2018, 2017, 2016, 2015, 2014, 2012, 2011
  • Award in Education, (Practice of Rheumatology) 2016-2017

   

BIOGRAPHY

Dr. Vivien Hsu earned her undergraduate degree from Rutgers University and Medical degree from New Jersey Medical School, Newark, NJ.  She completed her Internal Medicine training at University of California- Irvine/Long Beach VA Medical Center and University Hospital, Newark, NJ.  She completed her Rheumatology training at Rutgers- RWJ Medical School.   She returned to RWJMS as a faculty member and has served as the Director of the outpatient Rutgers- RWJ Scleroderma Program for over 20 years.

 

Clinical Interests and Description:

Dr. Hsu directs the only Scleroderma Program in the State of NJ, which has served as an important referral center for over 2 decades, managing all complications related to scleroderma spectrum disorders.   Dr. Hsu continues to conduct clinical research with the intent to find a cure and contributed to landmark trials which have increased our understanding and improved our management of this complex group of disabling rheumatic diseases.  Over the years, Dr. Hsu has mentored many who have become our future generation of rheumatologists.

 

Active research projects:

 

  • Prometheus /MERCK:  A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of PRA023 in Subjects with Systemic Sclerosis Associated with Interstitial Lung Disease (SSc-ILD) The  ATHENA-SSc-ILD Study

 

  • GSK Pharmaceutical: Efficacy and safety of Belimumab (GSK1550188) administered subcutaneously compared to placebo patients with dcSSc-ILD. (BLISS in SSc-ILD)

 

  • Project Title:  EUSTAR: Development and validation of preliminary classification criteria for scleroderma renal crisis (SRC)

 

PUBLICATIONS:

  • Spiera R, Kuwana M, Khanna D, Hummers L… Hsu, et al:  on behalf of RESOLVE-1 Study Group: Efficacy and Safety of Lenabasum, a Cannabinoid Type2 Receptor Agonist, in a Phase 3 Randomized Trial in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology 2023;75(9): 1609-1608.   PMID: 37098795

 

 
  • HsuVM, Kozak E, Li Q, Bocskai M, Schlesinger N, Rosenthal A. et al: Circulating levels of inorganic pyrophosphate reduced in patients with systemic sclerosis.  Rheumatology 2021; PMID: 34152415.

 

  • Hsu VM, Chung L, Hummers KL, Shah A, Simms R, Bolster et al: M. : Risk factors for mortality and cardiopulmonary hospitalization in scleroderma patients “at risk” for pulmonary hypertension in the PHAROS registry.  J Rheumatol 2018; jrheum.180018. doi: 10.3899/ (PMID: 30275260).

 

  • Van den Hoogen F, Khanna D, Fransen J, Johnson SR…Hsu VM et al: “Classification

      Criteria for  Systemic Sclerosis: An ACR-EULAR Collaborative  Initiative” Arthritis      

       Rheumatism  65 (11):2737-47, 2013 (PMID: 24122180)  and   Ann Rheum. Dis.

      72(11): 1747-55, 2013.  (PMID: 4092682.)

 

  • Tashkin DP., Elashoff R., Clements PJ., Roth MD., Furst DE., Hsu VM., et al: Effects of 1-Year treatment with Cyclophosphamide on Outcomes at 2 Years in  Scleroderma Lung Disease.   American Journal of Respiratory and Critical Care  Medicine  176:1026-1034, 2007.  (PMID:17717203)

 

Bibliography:

https://pubmed.ncbi.nlm.nih.gov/?term=Hsu%2C%20Vivien